Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. - Wikidata - wikimedia - TriplyDB

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

http://www.wikidata.org/entity/Q36020559

about

Antiproliferative Fate of the Tetraploid Formed after Mitotic Slippage and Its Promotion; A Novel Target for Cancer Therapy Based on Microtubule Poisons Development of cell-cycle checkpoint therapy for solid tumors Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC.Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance Mutant GDF15 presents a poor prognostic outcome for patients with oral squamous cell carcinoma Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.Objective assessment of the evolutionary action equation for the fitness effect of missense mutations across CAGI-blinded contests.Cytokinetic effects of Wee1 disruption in pancreatic cancer.Investigational drugs for head and neck cancer.TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.Molecularly targeted therapies for p53-mutant cancers.WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Evolutionary action and structural basis of the allosteric switch controlling β2AR functional selectivity.Directing the use of DDR kinase inhibitors in cancer treatment.Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.Targeting the DNA Damage Response in OSCC with TP53 Mutations.High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy Inhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma

P2860

Q26746973-7BF03A04-1D7A-47CE-81EB-F84C860C1BE9 Q26781187-E1DEA9C8-0AA9-49CC-A35B-45853AD600D3 Q28833606-3D170F0F-1498-4D5E-B65E-561115436A19 Q35698989-0B7D1724-99B1-4899-ACA4-1245087C02C1 Q36126403-62BAB51D-128E-48AA-8E0F-C64CC0090754 Q36244669-406543F9-9529-4825-BE93-80EF23C45EEF Q36297939-979A5910-584B-49C0-98EC-11EF6FEE7DA1 Q36739054-6A989882-FCAC-47B9-8EAA-4AF58BB2B695 Q38261022-4F7F91B0-5DA0-4461-88E4-0BFABA0991E6 Q38719309-43A1FD4A-E9B2-49FF-A34A-CE15C97DDFFF Q38764158-F6A315DD-2D2B-4381-9207-87A446A78A8B Q38793178-DF4EF5F1-D60A-4B89-AFC7-914CDF159677 Q38800788-2A3449E5-4EBD-45C0-9B1B-43C05A29986F Q38831709-26621E32-7B97-479D-B079-2D97D113856F Q38868212-3A531B05-E295-41AC-9D8E-CC97A8845578 Q39186868-A0748A63-9C62-410C-A3E3-F580405EA9D8 Q39393193-429ADA73-1C1A-4575-8780-6911485CAD6A Q41063971-33A3E90C-A75F-4975-B9C9-8C3EBF4832C8 Q42322707-AF638F6E-A378-4837-A5D8-55EA8AD51A77 Q45070718-6AD6B47E-2050-4A70-A13D-2EC1BFD20D6E Q45767716-AD9BC9DF-E5F0-4043-9932-D92B63B8B7C3 Q45790068-718545CE-ADC8-4ED9-A4C4-53B0D7CB794B Q47163312-697206D8-B83E-4D13-AF9E-060640BF55F0 Q47687840-23C3BA95-22F8-4380-ADAE-6FF823E403F8 Q47719669-6054A78D-7EBC-498A-9D4D-5E8FF3EED7AF Q48698494-10D5C66B-2EFA-4670-8A1F-1CE2F272A632 Q51740619-6F00F626-B73E-4FEB-BCB2-7E69D78CE745 Q52723099-2CB75654-FEA5-4D43-BACE-023ECE615EB2 Q52729908-EAB8A6FA-ECA7-466B-BD79-BC7B78D4D15C Q55027478-359C8D67-9542-4897-9837-59D230338D50 Q55445065-FFD60A43-CC1D-438E-B878-637C88C9F3FE Q55478403-A719DF25-F9F1-4D97-ABDB-8EC27AEA67F5 Q57138889-8E5FF585-4B53-429B-A124-35BFCB8DE8A8 Q57490219-08B092CA-7249-4587-BC59-5EC59092333E

P2860

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

http://www.wikidata.org/entity/Q36020559

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@ast

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@en

type

label

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@ast

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@en

prefLabel

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@ast

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@en

P1433

Q36020559-D723EA51-FCFA-4CD7-9019-46A90E4F417F

P1476

Q36020559-C41454C4-957F-4033-A277-4EF89D49A99E

P2093

Q36020559-01FF1711-3E70-4B8A-BC20-5956AD2BC916

Q36020559-09569D54-B5DD-43DC-9EFF-988E00758E2C

Q36020559-1C656B97-0E83-4554-93B7-D9596BE7AD0C

Q36020559-2613563F-81FC-4968-B09D-E47E9616A7BF

Q36020559-3A40D007-BBCA-48F3-B726-9D561866EEFD

Q36020559-7B9CA577-F0B4-481A-BD1E-08A305AAD023

Q36020559-A2BD0B9A-DBDF-4AE1-805B-F5A06865ECD4

Q36020559-A776C83E-FA10-4ED3-9701-47D5A1759DD6

Q36020559-ADCC3983-9F7E-45B3-85C9-6B24E1CD6EC2

Q36020559-AE9F9E5D-1D4F-41D6-A0B5-83B71C58B397

P2860

Q36020559-1DB818F5-0D3B-47E0-B346-518034285717

Q36020559-2AEC958C-6DA9-46F3-BDF3-8DFC17514B1B

Q36020559-2F00C6CC-E612-4CC9-B089-A05366C3A288

Q36020559-3AB3E389-5E4C-474E-9699-533E07573E99

Q36020559-3AC1D4BC-7FCA-40C6-B82E-3020304B8C36

Q36020559-3F6E4898-0F42-45FD-90ED-1B38103EA13F

Q36020559-5AA62093-F4B0-48A9-B132-933FCA037A7A

Q36020559-5FD32CFC-1004-4A5E-884B-12A222847DCD

Q36020559-60F0D7D5-B557-44F8-BB75-966390AEE0C3

Q36020559-73A4852D-8539-4FA4-BEAE-6BDFE08BA802

P304

Q36020559-2DEC360F-91A6-4091-AEA7-DBF70933248F

P31

Q36020559-DD70AF3E-3D1B-4EFF-B557-5AAFDAB88128

P356

Q36020559-1A0F26D7-3163-401F-A84E-9EE84F286AF4

P433

Q36020559-EB09D42F-1A2F-4E45-B394-6E7E0BF6CED9

P478

Q36020559-6CC5A95D-0A97-4CCD-AF4F-7A44ABE9CCF3

P50

Q36020559-7E806B38-6E13-4CF6-91D6-E8BB1D8372EE

P577

Q36020559-485AD9CD-D33D-4170-96FB-158CAEFEDF31

P5875

Q36020559-F3359C07-564E-447A-9ACA-0F17EFD5EDEC

P698

Q36020559-17BBC4FD-8DF9-40CC-8F06-64256FDED428

P932

Q36020559-9ED40FDD-77CF-4633-BB6B-2785A2C22B20

P356

1535-7163.MCT-14-0735-T

P1433

Molecular Cancer Therapeutics

P1476

Wee-1 kinase inhibition overco ...... arrest followed by senescence.

@en

P2093

Abdullah A Osman

http://www.w3.org/2001/XMLSchema#string

Alison L Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Ameeta A Patel

http://www.w3.org/2001/XMLSchema#string

Carlos Caulin

http://www.w3.org/2001/XMLSchema#string

David M Neskey

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Myers

http://www.w3.org/2001/XMLSchema#string

Marcus M Monroe

http://www.w3.org/2001/XMLSchema#string

Marcus V Ortega Alves

http://www.w3.org/2001/XMLSchema#string

Marek Kimmel

http://www.w3.org/2001/XMLSchema#string

Mitchell J Frederick

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

The mutational landscape of head and neck squamous cell carcinoma

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2.

Functional kinomics identifies candidate therapeutic targets in head and neck cancer

P304

608-619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-14-0735-T

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Lichtarge

P577

2014-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269715912

http://www.w3.org/2001/XMLSchema#string

P698

25504633

http://www.w3.org/2001/XMLSchema#string

P932

4557970

http://www.w3.org/2001/XMLSchema#string